The journey of a novel bioconjugate into clinic is complex and uncertain. In this webinar, we explore the particular challenges when moving a bioconjugate candidate from early development into clinic. Our experts will share key considerations for de-risking this journey. From navigating the diverse conjugation technology landscape to designing a robust and scalable process through development. Several customer case studies will illustrate how Lonza’s expertise and integrated solutions have helped drug developers to bring their innovative therapeutics to life
Additional Author: Sandro Holzer, Head of Process Development Bioconjugates, Lonza
Author(s):
Raphael Frey, Ph.D.
Head of Early Development Bioconjugates